John Keller, Ph.D., President and Chief Executive Officer
Dr. Keller joined Shionogi Inc. in July of 2010, as Executive Vice President, Corporate Development and Strategy, and was appointed as President and Chief Executive Officer and as a member of the Shionogi Inc. Board of Directors in April 2011. In April 2013, Dr. Keller was appointed as a Corporate Officer of Shionogi & Co., Ltd., and was promoted to Senior Executive Officer in April 2017.
Immediately prior to joining Shionogi, Dr. Keller was a Partner in SR One, the venture capital group of GlaxoSmithKline. Previously, Dr. Keller served as Executive Vice President and Chief Business Officer of Incyte Corporation, playing a key role in its transformation into a drug discovery and development company and establishing its first major corporate alliance after that transformation. Before Incyte, Dr. Keller had a 16 year tenure at GlaxoSmithKline and its predecessor, SmithKline Beecham, culminating in the position of Vice President, Worldwide Business Development. In that role, he structured numerous licensing agreements with a broad range of partners worldwide, including the agreements establishing the Shionogi-GSK Pharmaceuticals joint venture, which later evolved into the current relationship between ViiV Healthcare and Shionogi in the HIV area. Earlier positions encompassed R&D strategy, technology licensing, alliance management, public policy, project management, and drug discovery research.
Dr. Keller holds a Ph.D. in Microbiology from Rutgers University and a B.A. in Biology from Johns Hopkins University.